Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026
Globe Newswire•14/10/2026•08:00 ET
0
Key Highlights
- ➤Daxor (DXR) reports strong clinician interest in next-generation BVA technology
- ➤BVA exceeded 95% accuracy with streamlined workflow and rapid result delivery
- ➤Mechanical heart-pump patients had missed fluid overload and true anemia in 38% of cases
- ➤BVA-guided therapy produced statistically significant improvement in patient diuresis (p = 0.02)
- ➤238-patient study identified plasma volume reserve depletion from hidden red blood cell abnormalities
Expert Statements
John L. Jefferies, Chief Medical Officer of Daxor Corporation
“The latest clinical data presented at HFSA reaffirms what we consistently see in practice: relying on clinical guesswork leads to misdiagnosis in nearly 40% of complex heart failure cases.”
John L. Jefferies, Chief Medical Officer of Daxor Corporation
“By providing precise, direct quantification of both plasma volume and red blood cell mass, BVA empowers care teams to move beyond one-size-fits-all diuresis—tailoring targeted therapies that measurably improve decongestion while reducing costly hospital stays and readmissions.”
New Clinical Studies Validate BVA(™) Technology in High-Acuity Heart Failure Populations to Enhance Care
OAK RIDGE, TN, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced significant clinician interest and compelling clinical validation following the Heart Failure Society of America (HFSA) 2026 Annual Scientific Meeting.
Get started
Create a free account to read the full story.